AXONA® DELIVERS SIGNIFICANT
IMPROVEMENTS IN COGNITIVE FUNCTION
Clinical studies in Alzheimer’s disease1
Axona was evaluated in a double-blind, randomized, placebo-controlled study performed at multiple US clinical centers in a population of 152 patients with probable mild to moderate Alzheimer’s disease.
Proven cognitive results demonstrated in clinical studies2
Significant difference between Axona (n = 77) and placebo (n = 63) groups
in change from baseline in total ADAS-Cog† scores at day 45
(P = 0.024)
- A 4.77-point difference was observed in change from baseline ADAS-Cog scores among ApoE4(-) patients receiving Axona vs. placebo at day 45 (P = 0.0005)
- A 6.26-point difference was observed in change from baseline ADAS-Cog scores between Axona vs. placebo dosage-compliant‡ ApoE4(-) patients at day 45 (P = 0.001)
Cognitive benefits maintained over time2
AD patients taking Axona maintained a slight improvement from baseline after 90 days of daily administration, whereas the placebo group still demonstrated a decline (P = 0.0767)§
- A 3.36-point difference was observed in change from baseline ADAS-Cog scores among ApoE4(-) patients receiving Axona vs. placebo at day 90 (P = 0.015)
- A 5.33-point difference was observed in change from baseline ADAS-Cog scores between Axona vs. placebo dosage-compliant ApoE4(-) patients at day 90 (P = 0.006)
References: 1. Axona, [Prescribing Information]. Broomfield, CO: Accera, Inc.; September 2009. 2. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31.
† ADAS-Cog, Alzheimer’s Disease Assessment Scale—Cognitive subscale.
‡ Dosage-compliant subjects were defined as those who reported consuming
a total cumulative dose of at least 80% of the total intended dose.
§ P = 0.0767; the difference between groups was not statistically significant
at 90 days.
